B.Riley initiates Gen Digital stock with Buy rating on fintech expansion

B.Riley initiated coverage on Gen Digital Inc. (NASDAQ:GEN) with a Buy rating and a $46 price target, citing the company's strong position as a consumer-facing SaaS and fintech platform. The firm views Gen Digital's recent acquisition of MoneyLion as a significant catalyst, expected to accelerate revenue and EPS growth, building on robust Q4 2025 results that saw revenue increase 5% to $1.01 billion and non-GAAP EPS grow 14-15% to $2.22. With a solid 80.28% gross margin and FY2026 revenue guidance of $4.7-4.8 billion, Gen Digital is strategically positioned for continued expansion in cybersecurity and financial wellness.

Analysis

B.Riley has initiated coverage on Gen Digital Inc. (GEN) with a 'Buy' rating and a $46.00 price target, signaling strong confidence in the company's strategic direction. This outlook is underpinned by GEN's robust financial profile, which includes a formidable 80.28% gross margin, and is further validated by recent performance in Q4 2025, where revenue increased 5% year-over-year to $1.01 billion and non-GAAP EPS grew 14-15% to $2.22. The primary catalyst driving this optimism is the recent acquisition of MoneyLion, which B.Riley identifies as a 'fundamental step-change' expected to accelerate revenue and EPS growth by integrating a fintech marketplace with GEN's established cybersecurity and trust-based services. This strategic pivot is supported by a growing customer base, which expanded by 1.3 million to 40.4 million, and a confident FY2026 revenue forecast of $4.7-4.8 billion, implying 6-8% pro forma growth.

Key Decisions for Investors

• Given the positive analyst initiation, strong fundamentals, and a clear growth catalyst from the MoneyLion acquisition, investors could consider current levels an attractive entry point for establishing or adding to a long position.
• The central risk and opportunity lies in the successful integration of MoneyLion; investors should closely monitor upcoming quarterly reports for evidence of revenue synergies and margin improvements to validate the investment thesis.
• Investors should use the $46.00 price target as a key performance benchmark and monitor for further commentary from other analysts tracking the company's strategic pivot into financial wellness services.